Vnitr Lek 2005, 51(6):741-751

Practice guidelines for diagnosis and therapy of essential thrombocytaemia and thrombocytaemia associated with other myeloproliferative diseases

M. Penka^1,*, J. Schwarz², R. Pytlík³, M. Doubek⁴, Y. Brychtová⁴, P. Dulíček⁵

¹ Oddělení klinické hematologie FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Miroslav Penka, CSc.

² Ústav hematologie a krevní transfuze, Praha, ředitel prof. MUDr. Pavel Klener, DrSc.

³ I. interní klinika 1. lékařské fakulty UK a VFN, Praha, přednosta prof. MUDr. Pavel Klener, DrSc.

⁴ Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Vorlíček, CSc.

⁵ Oddělení klinické hematologie - II. interní klinika Lékařské fakulty UK a FN, Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.

Essential thrombocytaemia (ET) is not a frequent disease (incidence rate is about 0.1-1.5 cases per 100,000 persons) but as new approaches and possibilities advancing the standard care but contrariwise requiring responsible and systematic approach occur both in relationship with diagnosis and with treatment, it is necessary to deal appropriately with this problem. There is a variety of aspects, which evoke controversy within the scope of diagnosis and differential diagnosis - the most important thing is whether the histological examination of bone marrow is required or not and how to organise care of patients. All this relates not only to essential thrombocytopenia but also to myeloproliferative diseases associated with other myeloproliferative diseases at all (MPO-T). Enclosed recommended practice guidelines could help to serve as a guide in problems given without limiting the space for disputation.

Keywords: myeloproliferation; (essential) thrombocytaemia; megakaryopoesis; anagrelide; interferon; hydroxyurea

Received: May 2, 2005; Published: June 1, 2005  Show citation